Organic compounds -- part of the class 532-570 series – Organic compounds – Carboxylic acid esters
Patent
1992-12-22
1995-04-04
Dees, Jose G.
Organic compounds -- part of the class 532-570 series
Organic compounds
Carboxylic acid esters
C07C22934
Patent
active
054039517
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The present invention relates to organic chemistry, more particularly to a novel crystalline modification of 2-dimethylaminoethyl-n-butylaminobenzoate hydrochloride, a method of production thereof and a pharmaceutical preparation for anaesthesia of eyes, based thereon.
BACKGROUND ART
Known in the art is a crystalline modification of 2-dimethylaminoethyl-n-butylaminobenzoate hydrochloride (tetracaine), polymorphic form (R. C. Sullivan, K. P. O'Brien. X-ray diffraction studies of cocaine and its substitutes.--Bull. Narcotics, 1968, V.20, pp.31-40), characterized by the following set of interplanar spacings d and relative intensities of reflections I:
______________________________________ d, .ANG.
I
______________________________________
12.55 100
8.38 42
6.28 12
5.42 8
5.05 12
4.83 12
4.43 8
4.22 20
3.97 11
3.78 10
3.56 8
3.48 17
3.30 10
3.12 10
2.96 6
2.805 7
2.661 5
2.507 5
2.151 4
1.949 4
______________________________________
Also known in the art is a crystalline modification of 2-dimethylaminoethyl-n-butylaminobenzoate hydrochloride (amethocaine), polymorphic form (I. T. R. Owen, R. Sithiraks, F. A. Underwood. X-ray powder diffraction data for seventeen local anesthetics.--I. Ass. Off Analyt. Chem., 1972, V.55) characterized by the following set of interplanar spacings d and relative intensities of reflections I:
______________________________________ d, .ANG.
I d, .ANG.
I
______________________________________
13.3 10 3.22 7
8.06 10 3.17 10
6.55 40 3.08 9
6.23 20 3.03 7
6.02 40 3.00 7
5.73 6 2.94 4
5.07 6 2.87 6
4.78 15 2.82 12
4.50 25 2.77 9
4.39 13 2.71 6
4.23 20 2.66 7
4.05 15 2.62 6
3.98 18 2.58 6
3.83 25 2.54 7
3.73 12 2.50 4
3.65 100 2.46 6
3.57 10 2.42 6
3.45 20 2.32 6
3.40 7 2.28 6
3.28 6 2.24 6
2.15 6
______________________________________
Melting point of specified modifications is in the range of from 147.degree. to 151.degree. C. In this case, the process of melting of these modifications is a sequence of two endothermal effects (R. Curini, S. Zamponi, F. D'Ascenzo, S. De Angelis Curtis, A. Marino, A. Dezzi, Thermal analytical techniques applied to the narcotic field: cocaine analysis.--Thermochim. Acta, 1989, V.153, N I. pp.11-26).
Known in the art is a method for production of said modifications of 2-dimethylaminoethyl-n-butylaminobenzoate hydrochloride, comprising a process of n-butylation of .beta.-dimethylaminoethyl-para-aminobenzoate with subsequent crystallization of the obtained product in the mixture with hydrosulfite and carbon from ethyl alcohol at 2.degree.-3.degree. C. and drying (Synthetic chemico-pharmaceutical preparations, "Meditsina", (Moscow), 1971, pp.75-77).
The obtained product represents the aforementioned crystalline modifications characterized by the specified set of values d and I. Melting point of the obtained compound is in the range of 147.degree.-151.degree. C. with two subsequent endothermal effects.
The obtained product is a white crystalline powder having a slightly bitter taste, which causes temporary anaesthesia of the tongue, soluble in water and alcohol, moderately soluble in chloroform and practically insoluble in ether.
The known crystalline modifications of said compound, showing an effect of local anaesthesia, are highly toxic.
Besides, the known modifications of said compound have considerable side effects and when pharmaceutical preparations based on these compounds are used in ophthalmosurgery, they cause eyelid edema, injury to cornea epithelium, erosions, considerable dilation of conjuctiva. Eye drops based on these compounds are unstable in storage (term of validity is 3 months on condition of additional stabilization of the solution).
The crystallization modification of 2-dimethylaminoethyl-n-butylaminobenzoate hydrochloride according to the invention, method of its production and application are novel and haven't been described in the literature.
SUMMARY OF THE INVENTION
The invention is based on the problem to prov
REFERENCES:
Owens, J. Ass. Off. Anal. Chem. 55(6) 1171-4, (1972).
Mashkovsky, M. D., "Medications", vol. 1, 1986, Meditsina (Moscow), pp. 325-328.
International Pharmacopoeia, 3rd ed., vol. 3, "Specification for Controlling Quality of Pharmacutical Preparations".
World Health Organization, Geneva, 1988, pp. 357-359.
Rubtsov, M. V. et al., "Synthetic Chemical . . . Substances", Medistina Publishers, Moscow, 1971, pp. 73-77.
Curini, R. et al., "Thermal Analytical Technique . . . Analysis", Thermochimica Acta, 153(1989), pp. 11-26.
Conrad III Joseph
Dees Jos,e G.
LandOfFree
Crystalline modification of 2-dimethylaminoethyl-n-butylaminoben does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Crystalline modification of 2-dimethylaminoethyl-n-butylaminoben, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystalline modification of 2-dimethylaminoethyl-n-butylaminoben will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2381411